Pegzilarginase clinical trials
Also written AEB1102 and Co-ArgI-PEG.
How each study uses pegzilarginase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 23 Feb 2026 · LOARGYS · BLA 761211 (FDA, Drugs@FDA)
- European Union
- 15 Dec 2023 · Loargys · EMEA/H/C/005484 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2019 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Immedica Pharma AB (6) · Aeglea Biotherapeutics (2)
Studies
Open first, then newest update. How each study uses pegzilarginase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerTerminatedPhase 1/2Immedica Pharma ABNCT03371979Written as Pegzilarginase
- A Study of AEB1102 (Pegzilarginase) in Patients With Arginase 1 DeficiencyCompletedPhase 2Immedica Pharma ABNCT03378531Written as AEB1102
- Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 DeficiencyCompletedPhase 3Immedica Pharma ABNCT03921541Written as Pegzilarginase
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDSCompletedPhase 1Immedica Pharma ABNCT02732184Written as Co-ArgI-PEG modified human arginase I
- A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid TumorsCompletedPhase 1Immedica Pharma ABNCT02561234Written as Co-ArgI-PEG
- Pegzilarginase in Subjects <24 Months Old With Arginase 1 DeficiencyCompletedPhase 3Immedica Pharma ABNCT06582524Written as Pegzilarginase
- A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 DeficiencyTerminatedPhase 3Aeglea BiotherapeuticsNCT05676853Written as Pegzilarginase
- A Phase 1/2 Study of AEB1102 in Patients With Arginase I DeficiencyCompletedPhase 1/2Aeglea BiotherapeuticsNCT02488044Written as AEB1102
Codes
What other systems call pegzilarginase · ClinicalTrials.gg INT002211
- MeSH (NLM) C000732077pegzilarginaseOne source NLM
- UNII (FDA) 4YV4KW88GDPEGZILARGINASEConfirmed FDA, NLM, Wikidata
- Wikidata Q124038975pegzilarginaseConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C125143PegzilarginaseOne source FDA
- DrugBank DB14780One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000732077 | pegzilarginase | One source NLM |
| UNII (FDA) | 4YV4KW88GD | PEGZILARGINASE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q124038975 | pegzilarginase | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C125143 | Pegzilarginase | One source FDA |
| DrugBank | DB14780 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.